Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Britain's FTSE dips after Trump win though pharma, gold miners surge

Wed, 09th Nov 2016 09:58

(ADVISORY- Follow European and UK stock markets in real time onthe Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)

* FTSE 100 down 0.1 pct

* Gold miners, pharma stocks rally

* U.S.-exposed firms also gain

By Kit Rees

LONDON, Nov 9 (Reuters) - Britain's top share index fell onWednesday after a shock win for Republican Donald Trump in theU.S. presidential election sent markets lower, though goldminers and pharma stocks soared.

Trump defeated favourite Hillary Clinton in Tuesday'selection, putting the U.S. on an uncertain path and promptinginvestors to dump risky assets such as stocks.

The blue chip FTSE 100 index fell 0.1 percent to6,837.87 points by 0932 GMT, having rallied in the previoussession on expectation of a Clinton victory. The moredomestically-focused FTSE 250 index rose 0.2 pct.

The FTSE 100 had opened 2 percent lower, but recovered offits lows. Analysts cited Trump's acceptance speech as soothinginvestor nerves.

"I think the market over-reacted slightly this morning,"John Moore, advisory investment manager at Berkeley Capital,said, adding that he wouldn't be surprised if the FTSE 100turned positive.

"I think Trump is pro-business. The thing is, lookingtowards the FTSE, there are several stocks that will benefitfrom a Trump victory, such as the pharmaceuticals sector.Hillary Clinton wanted to impose tighter regulations, whereasTrump is opposed to that."

Healthcare stocks Hikma, Shire, Astrazeneca and GlaxoSmithKline rallied, gaining between 2percent to 6.7 percent on the back of Trump's win.

Pharma stocks had been losing ground in the run-up to theelection on worries that a Clinton presidency would put pressureon drug prices.

Some companies with significant exposure to the United Statesalso rose. CRH a construction firm which had been toutedas a potential beneficiary from any increase in U.S.infrastructure spending, jumped 7 percent, as it derives 50percent of its revenues from there. U.S.-focused Ashtead also soared 7.6 percent.

Investors' flight to safety buoyed shares in precious metalsminer Fresnillo, which jumped over 9 percent, alongwith Randgold Resources, which gained more than 7percent after the price of gold surged.

Shares in banking stocks, however, came underpressure, while British grocers fell after Sainsbury reported an underwhelming set of results and dropped 3.2percent. The supermarket reported a third straight decline infirst-half profit, hurt by a fall in sales. (Reporting by Kit Rees; Editing by Toby Chopra)

Related Shares

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...

Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.